Veronica Mollica

33PUBLICATIONS
73CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|May 13, 2026
Beyond One-Size-Fits-All Active Surveillance for Low-Risk Prostate Cancer: Risk-Adapted Follow-Up, De-Escalation Pathways, and Focal Therapy as Tailored Strategy.

|Mar 28, 2026
Oncofertility in Women with Renal Cell Carcinoma in the Immune Checkpoint Inhibitors Era: A Multidisciplinary Perspective.

Michele Miscia, Antonio Raffone, Veronica Mollica

|Jan 20, 2026
New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features.

Costantino Ricci, Luisa Di Sciascio, Francesca Ambrosi

|Sep 19, 2025
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors.

Sofia Melotti, Francesca Ambrosi, Tania Franceschini

|Sep 11, 2025
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study.

Costantino Ricci, Francesca Ambrosi, Tania Franceschini

|Sep 05, 2025
Correction to: The absence of FOXA2 and HNF1β expression in vasculogenic mesenchymal lesions of germ cell origin suggests an evolutionary pathway similar to that of sarcomatoid yolk sac tumor.

Costantino Ricci, Luisa Di Sciascio, Francesca Ambrosi

Pageof 6

Frequent Collaborators

26 joint publications

Francesco Massari

14 joint publications

Alessandro Rizzo

11 joint publications

Costantino Ricci

11 joint publications

Michelangelo Fiorentino